Immunofluorescence Assay Market by Product, Type, Disease, End-user and Region - Global Forecast to 2026

Dublin, Feb. 16, 2021 (GLOBE NEWSWIRE) -- The "Global Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End-user (Contract Research Organizations), and Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6% during the forecast period.

The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.

The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period

The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.

Indirect immunofluorescence segment accounted for the highest CAGR

Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.

Cancer segment accounted for the highest CAGR

Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. In 2020, the cancer segment accounted for the highest growth rate. Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment's growth.

Hospitals & Diagnostic Centers segment accounted for the highest CAGR

Based on end user, the immunofluorescence assays market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate. This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment's growth.

Asia-Pacific: The fastest-growing country in the Immunofluorescence assay market

The Immunofluorescence assay market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Asia-Pacific is projected to register the highest CAGR during the forecast period. Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia-Pacific.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Immunofluorescence Assays Market Overview
4.2 Asia-Pacific: Immunofluorescence Assays Market, by Type & Country (2020)
4.3 Immunofluorescence Assays Market: Geographic Growth Opportunities

5 Market Overview
5.1 Introduction
5.2 Key Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Prevalence of Chronic Diseases
5.2.1.2 Rising R&D and Healthcare Spending
5.2.1.3 Growing Industry-Academia Collaboration
5.2.1.4 Increasing Government Funding for Life Science Research
5.2.1.5 Growing Awareness About Early Disease Detection
5.2.2 Restraints
5.2.2.1 High Instrument Costs
5.2.3 Opportunities
5.2.3.1 High Growth Opportunities in Emerging Markets
5.2.4 Challenges
5.2.4.1 Quality Concerns Over Research Antibodies
5.2.4.2 Lack of Skilled Professionals
5.3 COVID-19 Impact on the Immunofluorescence Assays Market
5.4 Pricing Analysis
5.5 Value Chain Analysis
5.6 Supply Chain Analysis
5.7 Ecosystem Analysis of the Immunofluorescence Assays Market
5.8 PESTLE Analysis

6 Immunofluorescence Assay Market, by Product
6.1 Introduction
6.2 Reagents
6.2.1 Stains & Dyes
6.2.1.1 Stains and Dyes Accounted for the Largest Share of the Reagents Segment in 2020
6.2.2 Media & Sera
6.2.2.1 Serum-Free Media Eliminates the Risk of Contamination by Viruses
6.2.3 Fixatives
6.2.3.1 Fixative Agents are Required for the Preservation of Morphology and the Antigenicity of Target Molecules
6.2.4 Buffers
6.2.4.1 Buffers are Widely Used in Drug Development Applications
6.2.5 Probes
6.2.5.1 The Use of Probes in Research is Rising Owing to Its Versatile and Quantitative Capabilities
6.2.6 Solvents
6.2.6.1 Organic Solvents are Widely Used in Pharmaceutical Processes and Immunofluorescence Assays
6.2.7 Other Reagents
6.3 Instruments
6.3.1 Microscopes
6.3.1.1 Technological Advancements in Microscopy Techniques Propel Segment Growth
6.3.2 Imaging Analysis Systems
6.3.2.1 Imaging Analysis Systems are Widely Used in Diagnostics and Clinical Research
6.4 Antibodies
6.4.1 Primary Antibodies
6.4.1.1 The Increasing Demand for Accurate and Reliable Antibodies Coupled with Rising R&D Expenditure Drives Segment Growth
6.4.2 Secondary Antibodies
6.4.2.1 The Low Cost of Production and Versatility Have Ensured Stable Growth in the Market for Secondary Antibodies
6.5 Kits
6.5.1 The Demand for Complete Solutions Among End-users Drives the Growth of this Segment
6.6 Consumables & Accessories

7 Immunofluorescence Assay Market, by Type
7.1 Introduction
7.2 Indirect Immunofluorescence
7.2.1 Indirect Immunofluorescence Accounted for the Largest Share of the Market in 2020
7.3 Direct Immunofluorescence
7.3.1 The High Cost Associated with Direct Immunofluorescence May Limit the Growth of this Market

8 Immunofluorescence Assay Market, by Disease
8.1 Introduction
8.2 Cancer
8.2.1 Cancer Accounted for the Largest Share of the Disease Segment in 2020
8.3 Infectious Diseases
8.3.1 The Rising Prevalence of Infectious Diseases to Increase the Adoption of Immunofluorescence Assay Techniques
8.4 Cardiovascular Diseases
8.4.1 The High Incidence of CVD to Increase the Adoption of Immunofluorescence Imaging Techniques
8.5 Autoimmune Diseases
8.5.1 The Prevalence of Autoimmune Diseases Have Increased Worldwide, Thus Supporting the Growth of this Segment
8.6 Other Diseases

9 Immunofluorescence Assay Market, by End-user
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.2.1 Pharma & Biotech Companies Accounted for the Largest Share of the End-user Segment in 2020
9.3 Academic & Research Institutes
9.3.1 Growing Government Investments for R&D to Propel Market Growth
9.4 Hospitals & Diagnostic Centers
9.4.1 The Rising Prevalence of Chronic Diseases to Support the Growth of this Segment
9.5 Contract Research Organizations
9.5.1 Emerging Markets are Expected to Provide Robust Growth Opportunities for CROs

10 Immunofluorescence Assay Market, by Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Latin America
10.6 Middle East & Africa

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Scenario
11.3.1 Market Evaluation Framework, 2017-2020
11.3.2 Product Launches & Approvals
11.3.3 Agreements & Collaborations
11.3.4 Acquisitions
11.3.5 Expansions
11.3.6 Other Developments
11.4 Company Evaluation Matrix Definition and Methodology
11.4.1 Vendor Exclusion Criteria
11.4.2 Stars
11.4.3 Emerging Leaders
11.4.4 Pervasive Players
11.4.5 Participants
11.5 Competitive Leadership Mapping for Startups/SMEs
11.5.1 Progressive Companies
11.5.2 Starting Blocks
11.5.3 Responsive Companies
11.5.4 Dynamic Companies

12 Company Profiles
12.1 Thermo Fisher Scientific, Inc.
12.2 Abcam plc
12.3 Bio-Rad Laboratories, Inc.
12.4 Perkinelmer, Inc.
12.5 Merck KGaA
12.6 Werfen Company
12.7 Cell Signaling Technology, Inc.
12.8 MEDIPAN GmbH
12.9 Sino Biological, Inc.
12.10 Danaher Corporation
12.11 Maravai Lifesciences
12.12 Enzo Biochem, Inc.
12.13 Becton, Dickinson and Company (BD)
12.14 Olympus Corporation
12.15 Nikon Corporation
12.16 Bruker Corporation
12.17 Agilent Technologies
12.18 Zyagen, Inc.
12.19 Cellabs
12.20 J. Mitra & Co. Pvt. Ltd.
12.21 Abnova Corporation
12.22 EpiGentek Group
12.23 eLabscience, Inc.
12.24 AESKU Group GmbH
12.25 Maxvision Biosciences, Inc.

13 Appendix
13.1 Industry Insights
13.2 Discussion Guide
13.3 Knowledge Store: The Subscription Portal
13.4 Available Customizations

For more information about this report visit https://www.researchandmarkets.com/r/xmscdx

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900